Autoantibodies in myositis

Nature Reviews Rheumatology

Volumn 14, Issue 5, 2018, Pages 290-302

  McHugh, Neil J ^a   Tansley, Sarah L ^a  

^a University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; AMINO ACID TRANSFER RNA LIGASE; AUTOANTIBODY; AUTOANTIGEN; AUTOPHAGY RELATED PROTEIN 7; CYTOSOLIC 5' NUCLEOTIDASE 1A; HETERODIMER; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE (NADPH); INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; MYOSITIS ASSOCIATED AUTOANTIBODY; MYOSITIS SPECIFIC AUTOANTIBODY; NUCLEAR MATRIX PROTEIN; SIGNAL RECOGNITION PARTICLE; SYNTHETASE; TRANSCRIPTION FACTOR; TRANSCRIPTION INTERMEDIARY FACTOR 1 GAMMA; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTISYNTHETASE SYNDROME; CARCINOGENESIS; CELLULAR DISTRIBUTION; CLINICAL EVALUATION; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; COMORBIDITY; CYTOPLASM; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNE MEDIATED NECROTIZING MYOPATHY; IMMUNOASSAY; IMMUNOPATHOGENESIS; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; LUNG DISEASE; MALIGNANT NEOPLASM; MYOSITIS; PATHOGENESIS; PATIENT CARE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; SKIN DISEASE; ADULT; CHILD; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PERSONALIZED MEDICINE;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; CHILD; HUMANS; MYOSITIS; PHENOTYPE; PRECISION MEDICINE;

EID: 85045944684     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2018.56     Document Type: Review

References (118)

1. Larman, H. B. et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann. Neurol. 73, 408-418 (2013).
2. Pluk, H. et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann. Neurol. 73, 397-407 (2013).
3. Trallero-Araguas, E. et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 64, 523-532 (2012).
4. Mammen, A. L. et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 63, 713-721 (2011).
5. Betteridge, Z. & McHugh, N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J. Intern. Med. 280, 8-23 (2016).
6. Tansley, S. L. et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J. Autoimmun. 84, 55-64 (2017).
7. Love, L. A. et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70, 360-374 (1991).
8. Casciola-Rosen, L. et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J. Exp. Med. 201, 591-601 (2005).
9. Mohassel, P., Rosen, P., Casciola-Rosen, L., Pak, K. & Mammen, A. L. Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle. Arthritis Rheumatol. 67, 266-272 (2015).
10. Amaral Silva, M., Cogollo, E. & Isenberg, D. A. Why do patients with myositis die? A retrospective analysis of a single-centre cohort. Clin. Exp. Rheumatol. 34, 820-826 (2016).
11. Johnson, C. et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194, 733-737 (2016).
12. Koga, T. et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51, 1278-1284 (2012).
13. Vancsa, A. et al. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol. Int. 29, 989-994 (2009).
14. La Corte, R., Lo Mo Naco, A., Locaputo, A., Dolzani, F. & Trotta, F. In patients with antisynthetase syndrome the occurrence of anti-Ro/ SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39, 249-253 (2006).
15. Marie, I. et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 63, 3439-3447 (2011).
16. Witt, L. J., Curran, J. J. & Strek, M. E. The diagnosis and treatment of antisynthetase syndrome. Clin. Pulm. Med. 23, 218-226 (2016).
17. Nishikai, M. & Reichlin, M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 23, 881-888 (1980).
18. Mescam-Mancini, L. et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 138, 2485-2492 (2015).
19. Hamaguchi, Y. et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLOS ONE 8, e60442 (2013).
20. Klein, M. et al. Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations. J. Rheumatol. 41, 1133-1139 (2014).
21. Shi, J. et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J. Rheumatol. 44, 1051-1057 (2017).
22. Rider, L. G. et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 92, 223-243 (2013).
23. Huber, A. M. et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res. 66, 732-740 (2014).
24. Basharat, P. & Christopher-Stine, L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr. Rheumatol. Rep. 17, 72 (2015).
25. Pinal-Fernandez, I. et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 69, 263-270 (2017).
26. Kao, A. H., Lacomis, D., Lucas, M., Fertig, N. & Oddis, C. V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 50, 209-215 (2004).
27. Hengstman, G. J. et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann. Rheum. Dis. 65, 1635-1638 (2006).
28. Suzuki, S. et al. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch. Neurol. 69, 728-732 (2012).
29. Binns, E. L. et al. Effective induction therapy for anti-SRP associated myositis in childhood: a small case series and review of the literature. Pediatr. Rheumatol. 15, 77 (2017).
30. Allenbach, Y. et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine 93, 150-157 (2014).
31. Mammen, A. L. Necrotizing myopathies: beyond statins. Curr. Opin. Rheumatol. 26, 679-683 (2014).
32. Tansley, S. L. et al. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J. Rheumatol. 44, 488-492 (2017).
33. Kishi, T. et al. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1∗07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res. 69, 1088-1094 (2017).
34. Tiniakou, E. et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology 56, 787-794 (2017).
35. Sigurgeirsson, B., Lindelof, B., Edhag, O. & Allander, E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N. Engl. J. Med. 326, 363-367 (1992).
36. Hoshino, K. et al. Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology 49, 1726-1733 (2010).
37. Fujimoto, M. et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 64, 513-522 (2012).
38. Ichimura, Y. et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann. Rheum. Dis. 71, 710-713 (2012).
39. Fiorentino, D. F. et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 65, 2954-2962 (2013).
40. Albayda, J. et al. Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk. Arthritis Care Res., 69, 1771-1776 (2017).
41. Rogers, A., Chung, L., Li, S., Casciola-Rosen, L. & Fiorentino, D. F. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 69, 1909-1914 (2017).
42. Kijanka, G. et al. Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut 59, 69-78 (2010).
43. Shah, A. A. et al. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clin. Exp. Rheumatol. 35 (Suppl. 106), 71-74 (2017).
44. Dutton, K. & Soden, M. Malignancy screening in autoimmune myositis amongst Australian rheumato-logists. Intern. Med. J. 47, 1367-1375 (2017).
45. Hengstman, G. J. et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen. Ann. Rheum. Dis. 65, 242-245 (2006).
46. Ceribelli, A. et al. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin. Rheumatol. 36, 469-475 (2017).
47. Allenbach, Y. et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 139, 2131-2135 (2016).
48. Yang, H. et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res. Ther. 19, 259 (2017).
49. Watanabe, K. et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir. Med. 105, 1238-1247 (2011).
50. Aggarwal, R. et al. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis. Rheumatology 56, 384-389 (2017).
51. Aggarwal, R. et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann. Rheum. Dis. 73, 227-232 (2014).
52. Hervier, B. et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun. Rev. 12, 210-217 (2012).
53. Lega, J. C. et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun. Rev. 13, 883-891 (2014).
54. Mahler, M. & Raijmakers, R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun. Rev. 6, 432-437 (2007).
55. Sato, S. et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60, 2193-2200 (2009).
56. Gono, T. et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51, 1563-1570 (2012).
57. Kobayashi, I. et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J. Pediatr. 158, 675-677 (2011).
58. Kobayashi, N. et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology 54, 784-791 (2015).
59. Fiorentino, D., Chung, L., Zwerner, J., Rosen, A. & Casciola-Rosen, L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J. Am. Acad. Dermatol. 65, 25-34 (2011).
60. Hall, J. C. et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 65, 1307-1315 (2013).
61. Moghadam-Kia, S., Oddis, C. V., Sato, S., Kuwana, M. & Aggarwal, R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res. 68, 689-694 (2016).
62. Tansley, S. L. et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res. Ther. 16, R138 (2014).
63. Narang, N. S., Casciola-Rosen, L., Li, S., Chung, L. & Fiorentino, D. F. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res. 67, 667-672 (2015).
64. Fiorentino, D. F. et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J. Am. Acad. Dermatol. 72, 449-455 (2015).
65. Bailey, E. E. & Fiorentino, D. F. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr. Rheumatol. Rep. 16, 465 (2014).
66. Betteridge, Z. E. et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann. Rheum. Dis. 68, 1621-1625 (2009).
67. Sato, S. et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52, 1571-1576 (2005).
68. Habers, G. E. et al. Association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis. Arthritis Rheumatol. 68, 761-768 (2016).
69. Tansley, S. L. et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology 53, 2204-2208 (2014).
70. Fredi, M. et al. Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. Clin. Exp. Rheumatol. 35, 303-308 (2017).
71. Ceribelli, A. et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res. Ther. 14, R97 (2012).
72. Valenzuela, A., Chung, L., Casciola-Rosen, L. & Fiorentino, D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol. 150, 724-729 (2014).
73. Benveniste, O. et al. Long-term observational study of sporadic inclusion body myositis. Brain 134, 3176-3184 (2011).
74. Lilleker, J. B. et al. Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann. Rheum. Dis. 76, 862-868 (2017).
75. Herbert, M. K. et al. Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann. Rheum. Dis. 75, 696-701 (2016).
76. Aggarwal, R. et al. A negative antinuclear antibody does not indicate autoantibody negativity in myositis: role of anticytoplasmic antibody as a screening test for antisynthetase syndrome. J. Rheumatol. 44, 223-229 (2016).
77. Bundell, C., Rojana-Udomsart, A., Mastaglia, F., Hollingsworth, P. & McLean-Tooke, A. Diagnostic performance of a commercial immunoblot assay for myositis antibody testing. Pathology 48, 363-366 (2016).
78. Cavazzana, I. et al. Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J. Immunol. Methods 433, 1-5 (2016).
79. O'Hanlon, T. P. et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A,-B,-Cw,-DRB1, and-DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine 85, 111-127 (2006).
80. Chinoy, H. et al. HLA-DPB1 associations differ between DRB1∗03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology 48, 1213-1217 (2009).
81. Miller, F. W. et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun. 16, 470-480 (2015).
82. Rothwell, S. et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann. Rheum. Dis. 75, 1558-1566 (2016).
83. Gono, T. et al. Association of HLA-DRB1∗0101/∗0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 64, 3736-3740 (2012).
84. Targoff, I. N. et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 54, 3682-3689 (2006).
85. Mammen, A. L. et al. Increased frequency of DRB1∗11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res. 64, 1233-1237 (2012).
86. O'Hanlon, T. P. et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum. 54, 3670-3681 (2006).
87. Burd, C. J., Kinyamu, H. K., Miller, F. W. & Archer, T. K. UV radiation regulates Mi-2 through protein translation and stability. J. Biol. Chem. 283, 34976-34982 (2008).
88. Love, L. A. et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 60, 2499-2504 (2009).
89. Okada, S. et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 48, 2285-2293 (2003).
90. Sarkar, K. et al. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum. 52, 2433-2438 (2005).
91. Morikawa, S. et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J. Atheroscler. Thromb. 12, 121-131 (2005).
92. Watanabe, Y. et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine 94, e416 (2015).
93. Chinoy, H. et al. Interaction of HLA-DRB1∗03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann. Rheum. Dis. 71, 961-965 (2012).
94. Mammen, A. L. et al. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 60, 3784-3793 (2009).
95. Joseph, C. G. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343, 152-157 (2014).
96. Pinal-Fernandez, I. et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology 57, 388-396 (2018).
97. Aussy, A., Boyer, O. & Cordel, N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front. Immunol. 8, 992 (2017).
98. Pinal-Fernandez, I. et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology 56, 999-1007 (2017).
99. Aggarwal, R. et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology 55, 991-999 (2016).
100. Vermaak, E., Tansley, S. L. & McHugh, N. J. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin. Rheumatol. 34, 2089-2095 (2015).
101. Rider, L. G. & Miller, F. W. Laboratory evaluation of the inflammatory myopathies. Clin. Diagn. Lab. Immunol. 2, 1-9 (1995).
102. Stone, K. B. et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 56, 3125-3131 (2007).
103. Muro, Y., Sugiura, K., Hoshino, K. & Akiyama, M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology 51, 800-804 (2012).
104. Mahler, M., Miller, F. W. & Fritzler, M. J. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun. Rev. 13, 367-371 (2014).
105. Reichlin, M. & Mattioli, M. Description of a serological reaction characteristic of polymyositis. Clin. Immunol. Immunopathol. 5, 12-20 (1976).
106. Mathews, M. B., Reichlin, M., Hughes, G. R. & Bernstein, R. M. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J. Exp. Med. 160, 420-434 (1984).
107. Reeves, W. H., Nigam, S. K. & Blobel, G. Human autoantibodies reactive with the signal-recognition particle. Proc. Natl Acad. Sci. USA 83, 9507-9511 (1986).
108. Bunn, C. C., Bernstein, R. M. & Mathews, M. B. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J. Exp. Med. 163, 1281-1291 (1986).
109. Targoff, I. N., Trieu, E. P., Plotz, P. H. & Miller, F. W. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 35, 821-830 (1992).
110. Targoff, I. N., Trieu, E. P. & Miller, F. W. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J. Clin. Invest. 91, 2556-2564 (1993).
111. Hirakata, M. et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J. immunol. 162, 2315-2320 (1999).
112. Hashish, L., Trieu, E. P., Sadanandan, P. & Targoff, I. N. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome. Arthritis Rheumatol. 52, S312 (2005).
113. Betteridge, Z., Gunawardena, H., North, J., Slinn, J. & McHugh, N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 46, 1005-1008 (2007).
114. Betteridge, Z., Gunawardena, H., North, J., Slinn, J. & McHugh, N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 56, 3132-3137 (2007).
115. Targoff, I. N., Trieu, E. P., Levy-Neto, M. & Oddis, C. V. Sera with autoantibodies to MJ antigen react with NXP2. Arthritis Rheumatol. 56, S787 (2007).
116. Oddis, C. et al. Clinical and serological characterisation of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum. 40 (Suppl.), 139 (1997).
117. Chinoy, H. et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/ associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res. Ther. 8, R13 (2006).
118. Mierau, R. et al. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum. 39, 868-876 (1996).